Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs

Next Previous
Trial Profile

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Otilimab (Primary) ; Antirheumatics; Tofacitinib
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms contRAst-2
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

  • 16 Oct 2023 This trial has been completed in the Spain (End Date: 27 Oct 2022), according to European Clinical Trials Database record.
  • 12 Sep 2023 Results reporting efficacy and safety of otilimab from two clinical trials (NCT03980483, NCT03970837) published in the Annals of the Rheumatic Diseases
  • 15 Feb 2023 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top